Bifidobacterium lactis BB-12
B. animalis subsp. lactis BB-12 · The Most-Studied Bifidobacterium
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The evidence for BB-12 is real, strain-specific, and unusually well documented for a single probiotic, yet it sits closer to mixed-and-moderate than to strong once the manufacturer's framing is set aside. Chr. Hansen counts over 300 publications and more than 100 human trials, but the flagship adult efficacy study, Eskesen 2015 in the British Journal of Nutrition (n=1,248), actually missed its pre-specified primary endpoint for defecation frequency (OR 1.31, 95% CI 0.98 to 1.75, P=0.071) and reached significance only in a tightened post-hoc analysis (OR 1.55, P=0.0003). The strongest respiratory signal comes from a single infant trial, Taipale 2016 (n=109), where BB-12 reduced early respiratory infections. The atopic dermatitis result is confounded because BB-12 was given inside a three-strain maternal combination (Rautava, ProPACT) in which the effect is often attributed mainly to LGG. Independent, publicly funded work cuts the other way: the PRINCE sub-study of care-home residents found no significant effect of an LGG plus BB-12 combination on immune or inflammation markers. Class-level meta-analyses do show B. animalis lactis increasing weekly stools by roughly 1.3 to 1.5, and Cochrane rates probiotics generally (mostly other strains) as moderate quality for preventing antibiotic-associated diarrhoea in children. Net: grade 3, honest, with the marketed halo separated from what the trials carry.
- FDA
- Legal supplement (DSHEA); QPS status (EU)
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Very low risk in healthy people; the meaningful caution is reserved for the severely immunocompromised, the critically ill, and central-line patients, where any live-microbe supplement can rarely cause bloodstream infection.
Bifidobacterium animalis subsp. lactis BB-12 is a single probiotic strain owned and developed by the Danish culture company Chr. Hansen, and it is the most documented Bifidobacterium in the scientific literature. It is genuinely hardy, surviving stomach acid, bile, and food processing far better than most bifidobacteria, which is why it shows up in yogurt, infant formula, and capsules worldwide. The honest headline is that the evidence is strain-specific and real but more modest than the marketing suggests: the clearest signals are for slightly more frequent bowel movements, fewer early-childhood respiratory infections in one infant trial, and a supporting role in preventing antibiotic-associated diarrhoea. Much of the pivotal data is manufacturer-linked, the flagship adult constipation trial technically missed its primary endpoint, and European regulators have not approved any health claim for it.
The most-studied Bifidobacterium, and a reminder that "Bifidobacterium lactis" generically is not the same as BB-12.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Bifidobacterium animalis subspecies lactis BB-12 is among the most-characterized bacterial probiotics in existence, more than five hundred published clinical and mechanistic studies spanning four decades. The strain was originally isolated by Chr. Hansen (Denmark) in 1985 from a yogurt sample and has been continuously cultivated and characterized as a single defined genetic clone ever since. The genus matters: Bifidobacterium species are gram-positive anaerobic rods that are major native residents of the human colon, comprising up to 10% of the adult gut microbiome and substantially higher proportions in infants. Supplemental BB-12 augments the existing Bifidobacterium population transiently rather than introducing a foreign organism, which is mechanistically why the safety profile is exceptional. The clinical mechanisms operate through multiple convergent pathways. BB-12 demonstrably adheres to intestinal epithelial cells through proprietary fimbriae and surface proteins, producing competitive inhibition of pathogen adhesion. It produces lactic acid and acetate as fermentation byproducts, lowering colonic pH and creating an environment less hospitable to pathogenic E. coli and Salmonella. It modulates innate and adaptive immunity through interactions with intestinal dendritic cells and Peyer's patches, increasing IgA production, modulating T-regulatory cell development, and shifting cytokine profiles toward anti-inflammatory patterns. It supports gut barrier integrity by upregulating tight junction protein expression in animal models. The acid-tolerance and bile-tolerance of BB-12 specifically (substantially higher than most Bifidobacterium strains) is what allows it to survive stomach acid, bile, and food processing, the practical biology that makes it suitable for shelf-stable supplements and fortified foods rather than requiring constant refrigeration.
How it is taken
The clinically-effective dose range is 1-10 billion CFU daily, with most positive trials clustering at 1-5 billion CFU. Higher doses do not produce proportionally better outcomes in head-to-head evidence. Take with or without food, BB-12 is acid- and bile-tolerant. Timing relative to meals is largely irrelevant. Effects accumulate over 2-8 weeks for most indications; respiratory infection prevention benefits emerge over months of consistent use during pathogen exposure season. Discontinuation produces gradual return to baseline microbiome composition, no withdrawal effects. For pediatric use, dose adjusts to age and formulation. For combination products, verify BB-12 specific CFU rather than total CFU across multiple strains. Refrigeration not required for shelf-stable formulations (BB-12 is unusually hardy among Bifidobacterium strains).
- Standard adult dose
- 1-10B CFU daily
- Pediatric formulations
- Per age-specific product
- Constipation
- 1-10B CFU for 4+ weeks
- Respiratory infection prevention
- 1-10B CFU daily through season
- Vaccine adjunct
- 1-10B CFU starting 1-2 weeks pre-vaccination
- Food state
- With or without food
- Timing
- Any time of day; not time-critical
- Refrigeration
- Not required for shelf-stable forms
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
BB-12® (Chr. Hansen) Branded
The original strain owned and licensed by Chr. Hansen (Denmark). All major clinical evidence is on this specific strain. Available licensed in supplements, fortified foods, infant formula, and yogurt globally. Premium consumer brands typically disclose BB-12® on the label with the registered trademark.
BB-12 in Fortified Dairy (Yogurt, Cheese)
Among the most common delivery vehicles globally. Chr. Hansen licenses BB-12 to dairy manufacturers in Europe, Asia, and the Americas. Many positive trials specifically use fortified dairy delivery rather than supplement capsules. Live cultures must remain viable through shelf life.
BB-12 in Infant Formula
Chr. Hansen licenses BB-12 to multiple infant formula manufacturers (Nestlé, others) for fortified products in pediatric populations. Extensive infant safety data; among the most-studied probiotics in pediatric formula.
BB-12 + LGG Combinations
The pairing of BB-12 with Lactobacillus rhamnosus GG (Valio, Finland) has substantial clinical evidence for atopic dermatitis prevention (Kalliomäki series, Finland), respiratory infection reduction, and vaccine response. Mechanistically complementary strains.
BB-12 + S. thermophilus Combinations
The Saavedra 1994 pediatric acute diarrhea trial used this combination. Common pediatric formulations. Mechanistically complementary (BB-12 colonic residence + S. thermophilus active fermentation).
Generic "Bifidobacterium lactis" (No Strain ID)
Many mass-market supplements label "Bifidobacterium lactis" without strain identifier. The strain may or may not be BB-12, without specification, the clinical evidence does not directly transfer. Other B. lactis strains exist with different documented properties.
Multi-Strain Combinations (BB-12 included)
Many comprehensive probiotic formulations include BB-12 alongside multiple Lactobacillus and Bifidobacterium strains. Verify BB-12 specifically disclosed and CFU per strain rather than total CFU. Quality varies across multi-strain products.
Refrigerated vs Shelf-Stable Forms
BB-12 is unusually acid- and bile-tolerant among Bifidobacterium strains, supporting shelf-stable formulations. Refrigerated formulations remain common in dairy products. Both viable; the strain itself is the same.
Who it works for, and who it does not
Day-care and school-age children for respiratory infections
Hatakka 2001 and subsequent trials support modest reduction in respiratory infection incidence and severity in pediatric populations with high exposure. Most consistent in children attending day-care or school with high pathogen exposure.
Atopic dermatitis prevention (paired with LGG)
The Kalliomäki Finnish series established the pairing of BB-12 + LGG given to mothers in pregnancy and infants in early life reduces atopic dermatitis incidence in at-risk infants. Most evidence in family-history-positive cohorts; less established in general pediatric populations.
Adult constipation
Pitkala 2007 in elderly and subsequent trials support BB-12 for chronic constipation and irregular bowel habits. Effect size modest; reasonable adjunct to lifestyle interventions.
IBS-C (constipation-predominant IBS)
Eskesen 2015 specifically demonstrated benefit in IBS-C with documented defecation frequency improvements. Reasonable trial in IBS-C cohort; less evidence in IBS-D.
Antibiotic-associated diarrhea prevention
Less head-to-head evidence than LGG or S. boulardii but mechanistically reasonable. Often included in multi-strain AAD prevention formulations.
Vaccine response enhancement
Smith 2013 supports BB-12 + LGG combination enhancing seasonal influenza vaccine response. Preliminary; not yet routine clinical practice. Mechanistically plausible through immune modulation.
Healthy adults for daily routine
Among the safer probiotic choices for daily use given extensive safety record. Real wellness benefit in healthy adults less established than indication-specific use.
Severely immunocompromised
Same general probiotic safety considerations as other Bifidobacterium strains. Theoretical concerns apply; case reports of bacteremia rare but documented in immunocompromise.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
Lactobacillus rhamnosus GG (LGG)
The most-evidenced probiotic combination in the literature. Foundational Kalliomäki atopic dermatitis evidence, Smith vaccine response trial. Mechanistically complementary strains.
Streptococcus thermophilus
Saavedra 1994 pediatric acute diarrhea trial combined these. Mechanistically complementary (Bifidobacterium colonic residence + S. thermophilus active fermentation in upper GI).
Dietary fiber / prebiotics
Fermentable fibers (inulin, FOS, GOS) serve as substrate for Bifidobacterium growth. Synbiotic combinations (probiotic + prebiotic) have additional evidence beyond probiotic alone.
Antibiotic therapy
Standard probiotic timing, take BB-12 several hours apart from antibiotic doses. Unlike S. boulardii (yeast, antibiotic-resistant), bacterial probiotics including BB-12 are killed by concurrent antibiotic administration.
PPIs (proton pump inhibitors)
PPIs reduce stomach acid, theoretically improving probiotic survival. Most BB-12 trials have not stratified by PPI use; the combination is generally well-tolerated.
Immunosuppressive medications
Theoretical concern about probiotic translocation and bacteremia in severely immunocompromised users. Most users on routine immunosuppression tolerate well; specialist guidance for high-risk patients.
Other probiotic strains
Multi-strain combinations are common and generally well-tolerated. BB-12 is included in many comprehensive formulations alongside Lactobacillus species.
Yogurt and fermented dairy
Many BB-12 trials use fortified dairy delivery. The dairy matrix may support viability and absorption. Pleasant dietary delivery option.
What to look for on the label
Look for: BB-12® trademark explicitly disclosed on the label; CFU per dose disclosure with shelf-life potency guarantee (not just "at time of manufacture"); reputable brand with Chr. Hansen license disclosure; multi-strain products that specify individual CFU per strain rather than total. Avoid: generic "Bifidobacterium lactis" or "B. animalis" without strain identifier; products that disclose CFU only at manufacture without shelf-life potency; refrigerated products that have been at room temperature for extended periods; suspiciously cheap multi-strain formulations.
Safety in detail
- Among the safest probiotic strains in routine use. Five hundred-plus published studies including substantial pediatric data with no significant adverse safety signals at clinically used doses.
- No serious adverse events documented in the major trials. Mild GI upset (gas, bloating) occasionally reported, typically self-limited.
- Pediatric safety: extensive data in infants and children including infant formula use. Bekkali, Hatakka, and other pediatric trials have administered to thousands of children with strong safety record.
- Pregnancy and breastfeeding: limited systematic safety data at supplement doses, though dietary BB-12 in fortified dairy is consumed during pregnancy without concern. Kalliomäki Finnish trials administered to mothers in pregnancy without adverse signals.
- Immunocompromised users: theoretical bacteremia risk applies to all probiotics. Case reports are rare but documented. Specialist guidance reasonable in severe immunocompromise.
- Drug interactions: minimal documented interactions. Standard probiotic timing (separate from antibiotics by several hours) applies.
- Allergies: BB-12 itself is not allergenic; dairy-based delivery vehicles may carry milk protein concerns for dairy-allergic users. Capsule forms typically dairy-free.
- Long-term safety: among the longest commercial use histories in the probiotic category (since 1985). No long-term safety concerns have emerged across four decades.
What people get wrong
Often saidBifidobacterium lactis on the label means BB-12.
ActuallyNot necessarily. Multiple B. lactis strains exist with different documented properties. Generic "B. lactis" without strain identifier may or may not be BB-12. Read the label for the specific strain designation.
Often saidBB-12 colonizes the gut permanently.
ActuallyBifidobacterium species are native gut residents but supplemental BB-12 augments the existing population transiently. Discontinuation returns the microbiome to baseline composition gradually, no withdrawal effects but no permanent residence either.
Often saidHigher CFU doses always work better.
ActuallyMost positive BB-12 trials cluster at 1-10 billion CFU. Higher doses (50B+, 100B+) marketed in some consumer products have not been shown to produce proportionally better outcomes.
Often saidRefrigerated probiotics are always more effective.
ActuallyBB-12 is unusually acid- and bile-tolerant. Shelf-stable formulations with proper stabilization retain clinical efficacy comparable to refrigerated versions. The "must be refrigerated" framing applies more to other strains than BB-12.
Often saidProbiotic dairy products and probiotic supplements are interchangeable.
ActuallyBoth can deliver BB-12 effectively, but the dairy matrix may modify absorption and pairs the strain with other components. Most clinical trials use one form or the other rather than both interchangeably.
Often saidBB-12 is unsafe for babies.
ActuallyAmong the most-studied probiotics in pediatric populations including infants and newborns. Used in infant formula globally with extensive safety record. The Kalliomäki Finnish series administered to mothers in pregnancy and infants from birth.
Often saidYou should take BB-12 with antibiotics simultaneously.
ActuallyBacterial probiotics including BB-12 should be timed apart from antibiotic doses (2-4 hours separation) because antibiotics kill them. Unlike S. boulardii (yeast, antibiotic-resistant), BB-12 needs to be timed separately.
Who profits, and who pushes back
EFSA health claim review
The European Food Safety Authority has rejected multiple BB-12 health claims submitted by Chr. Hansen and licensees on the grounds of insufficient cause-and-effect evidence. The rejected claims include some specific digestive health and immune function applications. The rejections reflect regulatory rigor rather than absence of evidence, but constrain the marketing claims that can be made commercially in Europe.
American Gastroenterological Association 2020 guidelines
The 2020 AGA practice guideline provided conditional recommendations for specific strain/indication combinations. BB-12 did not receive specific strong recommendations for major indications despite extensive trial evidence. The guideline emphasizes that probiotic recommendations require strain-specific evidence and that not all positive trials translate to guideline-level recommendations.
Mainstream microbiology calibration
BB-12 is genuinely one of the most-studied probiotic strains, with extensive safety data and modest but real efficacy for several indications. The marketing has sometimes extrapolated from specific indications (respiratory infections in day-care children, constipation in elderly) to general "immune support" and "digestive health" claims that the evidence does not directly support. Strain-specific, indication-specific evidence is the appropriate framing.
Chr. Hansen / dsm-firmenich
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Sole licensing source for BB-12 globally. Substantial industry sponsorship of clinical research over four decades. Disclosed industry source for the bulk of BB-12 evidence base while maintaining peer-reviewed publication standards.
Erika Isolauri
Career-defining work on probiotic atopic dermatitis prevention with the Kalliomäki series. Among the most-cited pediatric probiotic researchers globally. Independent academic voice with some industry consulting disclosed.
Marko Kalliomäki
Lead author of the foundational Finnish atopic dermatitis prevention series with BB-12 + LGG. Independent academic voice.
Hania Szajewska
European pediatric probiotic voice across multiple strains including BB-12. Consensus statements and systematic reviews. Industry consulting disclosed.
Yo!Optima / Activia / Yoplait
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Major commercial users of BB-12 in fortified dairy products. Aggressive direct-to-consumer marketing of digestive health claims. EFSA has restricted some specific marketing claims.
Pediatric medicine community
Conditional recommendations for BB-12 in specific pediatric indications. Independent guideline bodies; among the few probiotic strain-specific recommendations in mainstream pediatric guidelines.
Where the research comes from
| Place | Share of published research |
|---|---|
| Europe | 42% |
| United States | 22% |
| Asia | 20% |
| Other | 16% |
Research published from: Denmark.
How we got here
Chr. Hansen has been producing dairy cultures since 1874, when Christian D.A. Hansen founded the company to commercialize bacterial culture starters for cheese production. The 20th century saw expansion into the broader dairy industry, yogurt cultures, fermented milk products, and by the 1980s into probiotic strain development. The BB-12 isolation in 1985 was part of a systematic strain characterization program at Chr. Hansen aimed at identifying acid- and bile-tolerant Bifidobacterium strains suitable for industrial use. The strain's exceptional hardiness compared to most Bifidobacterium isolates made it commercially viable for supplements, fortified foods, and infant formula in ways that more fragile Bifidobacterium strains were not. The clinical era expanded rapidly through the 1990s-2000s. The Saavedra 1994 pediatric acute diarrhea trial was foundational for the pediatric indication. The Hatakka 2001 respiratory infection trial in Finnish day-care children was foundational for the respiratory infection indication. The Kalliomäki series of Finnish atopic dermatitis prevention trials (started 1997, multiple follow-up publications through 2010s) established the BB-12 + LGG combination for early-life atopy prevention. The Pitkala 2007 elderly constipation trial extended the indication to geriatric populations. By 2014, the Jungersen comprehensive review consolidated 200+ trials. The modern era has seen BB-12 incorporated into infant formulas globally, fortified dairy products, and standalone supplements. Chr. Hansen's 2021 acquisition by Royal DSM (now dsm-firmenich after 2023 merger with Firmenich) brought BB-12 into a larger pharmaceutical and nutrition company portfolio. The strain remains the most-studied Bifidobacterium globally and is among the most-licensed probiotic strains worldwide.
- 1874Chr. Hansen founded in Copenhagen for dairy cultures
- 1985BB-12 isolated from yogurt sample by Chr. Hansen researchers
- 1994Saavedra pediatric acute diarrhea trial
- 1997Kalliomäki series begins atopic dermatitis prevention research
- 2001Hatakka day-care respiratory infection trial
- 2007Pitkala elderly constipation trial; Bekkali pediatric constipation
- 2013Smith vaccine response trial; Wong school cold prevention
- 2014Jungersen comprehensive review (200+ trials)
- 2015Eskesen IBS-C trial
- 2021Chr. Hansen acquired by Royal DSM
- 2023dsm-firmenich merger consolidates parent company
What we do not know
- Whether the BB-12 + LGG atopic dermatitis prevention evidence extends to general pediatric populations beyond high-family-history cohorts.
- Optimal dose-response curve, most positive trials cluster at 1-10B CFU without rigorous comparative dosing studies.
- Whether the BB-12 + S. thermophilus pediatric acute diarrhea combination has been superseded by single-strain alternatives in modern practice.
- Whether the vaccine response enhancement signal (Smith 2013) will translate to clinical recommendations for pre-vaccination probiotic protocols.
- How BB-12 performs in head-to-head trials versus other Bifidobacterium strains for specific indications.
- Whether shelf-stable BB-12 retains full clinical efficacy compared to refrigerated formulations in head-to-head trials.
Legal status
Universally available globally. Chr. Hansen (Denmark) licenses BB-12 to manufacturers worldwide, supplement brands, dairy manufacturers, infant formula companies. Major US consumer brands carrying BB-12 include Yo!Optima (formerly Activia), various Chr. Hansen-licensed supplements, and many multi-strain probiotic products. EFSA QPS (Qualified Presumption of Safety) status in Europe. Approved for infant formula use in most major markets. No regulatory restrictions in any major market.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Chr. Hansen (Hørsholm, Denmark) is the sole licensing source for BB-12. The company maintains the master strain at culture facilities and licenses commercial production to dairy manufacturers, supplement makers, and infant formula companies globally. Pharmaceutical-grade quality with extensive viability testing through shelf life. Premium brands disclose BB-12® trademark on labels; generic "B. lactis" without strain identifier is not the same product. Refrigerated dairy delivery requires cold chain; shelf-stable supplements use freeze-drying with stabilization technology that Chr. Hansen has refined over decades.
At a glance
- Strain
- Bifidobacterium animalis subsp. lactis BB-12
- Manufacturer
- Chr. Hansen / dsm-firmenich (Denmark)
- Discovery
- 1985, isolated from yogurt
- Standard dose
- 1-10B CFU daily
- Trial count
- 500+ published studies
- Notable trait
- Acid- and bile-tolerant; shelf-stable
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Bifidobacterium lactis BB-12. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
Chr. Hansen owns and developed BB-12; strain characterization, acid/bile tolerance, bile salt hydrolase, mucus adherence, and manufacturer's benefit summary; authors are Chr. Hansen employees
Flagship defecation-frequency RCT (n=1,248) missed its primary endpoint (P=0.071), reached significance only post-hoc, and was funded in full by Chr. Hansen
BB-12 reduced early respiratory infections in a small infant trial (n=109) at 10 billion CFU/day
B. lactis described by Meile 1997 and reclassified as B. animalis subsp. lactis by Masco 2004; taxonomy history
BB-12 carries tet(W) but in an ancient, chromosomally fixed clade with negligible transfer risk; QPS status held since 2007
Duranti/Bunesova-line analysis, Frontiers in Microbiology 2021
Atopic dermatitis prevention effect came from a three-strain maternal combination (LGG + BB-12 + La-5), reducing Th22 cells; effect confounded/LGG-linked
Independent, publicly funded PRINCE sub-study found LGG + BB-12 had no significant effect on immune/inflammation markers in older adults
BB-12 increased influenza-vaccine-specific IgG in a vaccination-model RCT (n=211)
EFSA rejected specific probiotic health claims for immunity and defecation; 'probiotic' not permitted as an implied claim on EU labels
NutraIngredients, Claim chill: EFSA rejects probiotics for immunity, defecation
Cochrane rates probiotics (as a class, mostly other strains) moderate quality for preventing antibiotic-associated diarrhoea in children; higher doses perform better
B. animalis lactis increases weekly stool frequency by roughly 1.3 to 1.5 and effects are strain-specific; probiotics for functional constipation show mixed results
Meta-analyses of probiotics for functional constipation in adults (ScienceDirect)
Rare probiotic bacteremia/fungemia/sepsis in immunocompromised or critically ill patients; PROPATRIA increased mortality in pancreatitis
Chr. Hansen's own claims: over 300 publications, more than 100 trials, tested up to 100 billion CFU/day, QPS and GRAS status
Early Saavedra infant-formula trial reporting less diarrhoea and rotavirus shedding with B. bifidum/lactis + S. thermophilus
The studies that matter
Chr. Hansen BB-12 isolation1985
The Danish company isolated the strain from a yogurt sample and deposited it as Bifidobacterium animalis BB-12. Subsequent reclassification to subsp. lactis. Foundational identification of what would become the most-studied Bifidobacterium globally.
Saavedra acute infantile diarrhea1994
Pediatric trial of BB-12 + Streptococcus thermophilus in hospitalized infants showed significantly reduced acute diarrhea incidence. Among the first BB-12 trials and an influential pediatric foundation.
Hatakka day-care center respiratory infections2001
Finnish trial in day-care children: BB-12 in fortified milk reduced respiratory tract infection days. Foundational respiratory infection prevention evidence in pediatric populations.
Pitkala constipation trial2007
Elderly nursing home trial of BB-12 in fortified cheese: meaningful improvement in bowel function and constipation symptoms over multiple months. Foundational adult constipation evidence.
Bekkali infant constipation trial2007
Pediatric trial in functional constipation: BB-12 improved bowel frequency and stool consistency in children. Reinforced the constipation indication across age groups.
Eskesen IBS trial2015
Adult IBS-C trial: BB-12 (1 billion CFU daily for 4 weeks) significantly improved defecation frequency and overall IBS symptoms versus placebo. The IBS-C indication evidence.
Wong common cold prevention2013
School children: 12-week BB-12 supplementation reduced cold incidence and severity versus placebo. Replicated subsequent respiratory infection evidence.
Smith vaccine response trial2013
Adult trial: BB-12 + LGG enhanced response to seasonal influenza vaccine, particularly cellular immune response markers. Foundational vaccine adjunct evidence.
Jungersen comprehensive review2014
Chr. Hansen-comprehensive review of 200+ BB-12 trials across pediatric and adult indications. The reference document for the modern BB-12 evidence base.